Regen BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGBP research report →
Price Chart
About the company
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene.
- CEO
- David Raymond Koos
- IPO
- 2014
- Employees
- 1
- HQ
- La Mesa, CA, US
Get TickerSpark's AI analysis on RGBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.15K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.01
- P/B
- -0.01
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
- Gross Margin
- 75.03%
- Op Margin
- -339.81%
- Net Margin
- -501.43%
- ROE
- 19.69%
- ROIC
- 16.23%
Latest fiscal year · YoY change
- Revenue
- $236.56K+0.0%
- Gross Profit
- $236.56K+0.0%
- Op Income
- $-338,540
- Net Income
- $-1,274,502-90.8%
- EPS
- $-0.05+66.1%
- OCF Growth
- +44.7%
- FCF Growth
- +44.7%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.23
- RSI (14)
- 47
- Avg Volume
- 30.30M
No earnings-call transcripts are available for RGBP yet.
- Free Float
- 96.5%
- Shares Outstanding
- 31.55M
- Float Shares
- 30.46M
of shares held by institutions
1 13F filers
Our RGBP coverage
Recent articles, reports, and earnings notes.
No research on RGBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGBP report →Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
globenewswire.com · Dec 9
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
accessnewswire.com · Nov 5
Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
accessnewswire.com · Jul 17
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™
globenewswire.com · Nov 19
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
globenewswire.com · Sep 23
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
prnewswire.com · Apr 2
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
prnewswire.com · Jan 8
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
prnewswire.com · Nov 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.